<DOC>
	<DOCNO>NCT01260805</DOCNO>
	<brief_summary>A Phase I , Open Label , Randomized , Two-way Crossover , Single Dose Study Determine Bioequivalence Ethinylestradiol + Gestodene - The objective study verify single dose study , two formulation Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coat tablet bioequivalent administer dose fasting condition .</brief_summary>
	<brief_title>A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers .</brief_title>
	<detailed_description>Bioequivalence Study</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Gestodene</mesh_term>
	<mesh_term>Femovan</mesh_term>
	<criteria>Healthy female subject childbearing age , age 18 45 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . The BMI Body Mass Index volunteer within range 18,5 24,9 ( Dietary Guidelines Americans ) may vary 10 % due upper limit ( 18,5 27,39 ) total body weight &gt; 50kg Do smoker ( least 3 month ) ; Not use hormone contraceptive least 28 day medication dosing ; Women regular menstrual cycle ( menstrual cycle occur , average , 28 day , vary 25 35 day ) ; Use lubricate condom spermicidal diaphragm spermicidal ( accordance volunteer 's preference ) Systolic Pressure 130mmHg ; Diastolic Pressure 85mmHg ; An informed consent document sign date subject legally acceptable representative . If subject and/or legally acceptable representative read , informed consent document may sign impartial witness . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . The volunteer drug abuse history [ subject use marijuana hashish exclude use drug less three month prior medical consult drug cocaine , phencyclidine ( PCP ) , crack heroin , volunteer exclude use drug less 1 year prior medical consult . A positive exam drug urine ( Methamphetamine , Opiate , Morphine , Marijuana , Cannabis , Amphetamine , Coccaine , Benzoylecgogine , Benzodiazepine ) positive test alcohol internment period 1 2 . History regular alcohol consumption exceed 7 drinks/week ( 1 drink = 150 mL wine 360 mL beer 45 mL hard liquor ) within 6 month screen . The volunteer smoker stop smoke less 3 month The volunteer participate experimental trial ingest experimental drug within 6 month precede begin study ( ANVISA : Resolution RDC nº34 , June 3rd 2008 ) . 12lead ECG demonstrate QTc &gt; 450 msec screening . If QTc exceed 450 msec , ECG repeat two time average three QTc value use determine subject 's eligibility . Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method nonhormonal contraception outline protocol least 14 day prior first dose study medication . Use prescription nonprescription drug dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Herbal medicine , herbal supplement must discontinue 28 day prior first dose study medication . Limited use nonprescription medication believe affect subject safety overall result study may permit casebycase basis follow approval sponsor . Hormonal method contraception ( include oral transdermal contraceptive , injectable progesterone , progestin subdermal implant , progesteronereleasing IUDs , postcoital contraceptive method ) hormone replacement therapy must discontinue 28 day prior first dose study medication . Implant ( ex . Norplant® ) progesterone depot injection ( ex . DepoProvera® ) use dispositive long term treatment progesterone estrogens ( ex . Estring® ) 6 month administration medication study ; A depot injection implant active ingredient 3 month administration medication study ; Have use injection contraceptive Medroxyprogesterone Acetate one year beginning study ; Have sexual intercourse without contraceptive method ( preservative , IUD , diaphragm spermicidal ) within last 14 day .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>bioequivalence</keyword>
	<keyword>study</keyword>
	<keyword>ethinylestradiol</keyword>
	<keyword>gestodene</keyword>
</DOC>